Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 7/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159654 | 0.82 | HDAC6 (0.56) | HDAC8HDAC6HDAC2 | |
| SCHEMBL6971854 | 0.80 | ALDH1A1 (0.46) | HPGDHTTSMN1; SMN2GAA | |
| SCHEMBL10716721 | 0.80 | KDM4E (0.48) | HTTCA2GAA | |
| SCHEMBL2883020 | 0.79 | TSHR (0.38) | TSHRHTTSMN1; SMN2CA2 | |
| SCHEMBL5253664 | 0.79 | CYP2C9 (0.44) | HTTSMN1; SMN2 | |
| SCHEMBL160225 | 0.79 | NPSR1 (0.47) | HPGDSMN1; SMN2 | |
| SCHEMBL158021 | 0.79 | GAA (0.41) | HDAC6HPGDSMN1; SMN2GAA | |
| SCHEMBL2073622 | 0.78 | P4HTM (0.43) | SMN1; SMN2 | |
| SCHEMBL28306417 | 0.78 | NAMPT (0.36) | HTTSMN1; SMN2GAA | |
| SCHEMBL8961219 | 0.77 | HDAC3 (0.32) | HDAC8HDAC6HDAC2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | claimed |
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | claimed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | MERCK PATENT GMBH (DE) | 2019-05-21 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | claimed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | claimed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | claimed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | claimed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | GPX4, GPX1, ACAT1 | HDAC8 377/4885HDAC6 91/4885HDAC2 62/4885 |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | HDAC8 172/4885HDAC6 375/4885HDAC2 202/4885 |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | HDAC8 505/4885HDAC6 1181/4885HDAC2 528/4885 |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | HDAC8 1286/4885HDAC6 980/4885HDAC2 410/4885 |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | PSMB7, PSMA7, PSMB11 | HDAC8 216/4885HDAC6 449/4885HDAC2 553/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | HDAC8 511/4885HDAC6 88/4885HDAC2 324/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HDAC8 1078/4885HDAC6 1060/4885HDAC2 919/4885 |
| US-10150767-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | HDAC8 64/4885HDAC6 20/4885HDAC2 21/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | HDAC8 511/4885HDAC6 88/4885HDAC2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.